U.S supercomputing chip-design firm Ceremorphic, which has a technology development centre in Hyderabad, is foraying into the life-sciences industry, specifically the drug discovery space, with an analog computing solution to accelerate the development cycle.
At the heart of the foray is the In Silico architecture it has developed using proprietary analog circuit technology, supercomputing chips and novel AI algorithms to simulate the human cell and its responses, founder Venkat Mattela said in an interaction here on Thursday.
With over 90% of the drug candidates not going past the clinical phase II and the small number of drugs getting the go ahead from the U.S. Food and Drug Administration, a new development methodology is required in the early stages of the design pipeline, he said.
